Clinical Trial Simulations for Dosage Optimization of Docetaxel in Patients with Liver Dysfunction, Based on a Log-binominal Regression for Febrile Neutropenia
This study was aimed to perform clinical trial simulations to evaluate the dose reduction strategy of docetaxel for Japanese patients with liver dysfunction, which we previously proposed. For this purpose, a log-binominal regression (LBR) was performed for febrile neutropenia (FN) induced by docetax...
Saved in:
| Published in | YAKUGAKU ZASSHI (Journal of the Pharmaceutical Society of Japan) Vol. 129; no. 6; pp. 749 - 757 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
Pharmaceutical Society of Japan
01.06.2009
|
| Online Access | Get full text |
| ISSN | 0031-6903 |
| DOI | 10.1248/yakushi.129.749 |
Cover
| Abstract | This study was aimed to perform clinical trial simulations to evaluate the dose reduction strategy of docetaxel for Japanese patients with liver dysfunction, which we previously proposed. For this purpose, a log-binominal regression (LBR) was performed for febrile neutropenia (FN) induced by docetaxel in these patients. A LBR analysis was conducted using clinical data from cancer patients treated with docetaxel and incorporated in the subsequent trial simulation. Virtual patients with liver dysfunction were randomly assigned to receive the Japanese standard dose (60 mg/m2) or reduced dose (40 or 50 mg/m2) of docetaxel. The primary endpoint was overall survival of the reduced dose to the standard dose. The secondary endpoint was the number of patients who experienced FN in response to the two treatment regimens. From the LBR analysis, the performance status and the area under the plasma concentration-time curve (AUC) were selected as covariates associated significantly (p<0.05) with FN occurrence. From the results of the present trial simulation, the median proportion of patients who experienced FN was decreased by about 20% in the reduced dose arm. Non-inferiority criteria, the reduced dose group to the standard dose group were met in 85.5% of the simulated clinical trials with a decrease in the FN frequency. In conclusion, clinical trial simulation models for the efficacy (survival) and toxicity (FN) was first performed in Japanese patients, and the feasibility of docetaxel therapy for liver-dysfunction patients under the dose reduction strategy was supported. |
|---|---|
| AbstractList | This study was aimed to perform clinical trial simulations to evaluate the dose reduction strategy of docetaxel for Japanese patients with liver dysfunction, which we previously proposed. For this purpose, a log-binominal regression (LBR) was performed for febrile neutropenia (FN) induced by docetaxel in these patients. A LBR analysis was conducted using clinical data from cancer patients treated with docetaxel and incorporated in the subsequent trial simulation. Virtual patients with liver dysfunction were randomly assigned to receive the Japanese standard dose (60 mg/m2) or reduced dose (40 or 50 mg/m2) of docetaxel. The primary endpoint was overall survival of the reduced dose to the standard dose. The secondary endpoint was the number of patients who experienced FN in response to the two treatment regimens. From the LBR analysis, the performance status and the area under the plasma concentration-time curve (AUC) were selected as covariates associated significantly (p<0.05) with FN occurrence. From the results of the present trial simulation, the median proportion of patients who experienced FN was decreased by about 20% in the reduced dose arm. Non-inferiority criteria, the reduced dose group to the standard dose group were met in 85.5% of the simulated clinical trials with a decrease in the FN frequency. In conclusion, clinical trial simulation models for the efficacy (survival) and toxicity (FN) was first performed in Japanese patients, and the feasibility of docetaxel therapy for liver-dysfunction patients under the dose reduction strategy was supported. |
| Author | Hitoshi SATOa Kazuhiro OZAWAa c Hironobu MINAMIb |
| Author_xml | – sequence: 1 fullname: Kazuhiro OZAWAa – sequence: 2 fullname: Hironobu MINAMIb – sequence: 3 fullname: c – sequence: 4 fullname: Hitoshi SATOa |
| BookMark | eNotkM1OwzAMx3MYEgN25poHoCNd2qQ9wmCANDEE41wlqbNldMnUtMB4GV4VD_DBlj_-tvU7IQMfPBBynrJxOsmKy7166-PaYVKOZVYOyJAxniaiZPyYjGJ0mrEJWp4WQ_I9bZx3RjV02Tr0L27bN6pzwUdqQ0tvQlQroItd57bu67dBg8WygU59QkOdp09YBt9F-uG6NZ27d0DdPtrem8P8Bb1WEWqKSkXnYZVo58PWebz2DKsW8CNsHY7NQLeuAfoIfdeGHXinzsiRVU2E0X88Ja-z2-X0Ppkv7h6mV_Nkw7O8S-raWA7aSMUFQqhTECznYISUsshkUWRWc6PtJEvLGqwVNteCS13XQssyN_yUzP72bqE-4AgeuUC1CX2Lj8bKRHnguqomjJUVQ7ZMYOAVQ8TocimyghUZ_wFi8Hte |
| ContentType | Journal Article |
| CorporateAuthor | National Cancer Center Hospital East bThe Division of Oncology/Hematology aDepartment of Clinical and Molecular Pharmacokinetics/Pharmacodynamics Kobe University Hospital and Graduate School of Medicine School of Pharmaceutical Sciences Department of Medicine Showa University cMedical Oncology |
| CorporateAuthor_xml | – name: School of Pharmaceutical Sciences – name: Showa University – name: bThe Division of Oncology/Hematology – name: Department of Medicine – name: Kobe University Hospital and Graduate School of Medicine – name: cMedical Oncology – name: aDepartment of Clinical and Molecular Pharmacokinetics/Pharmacodynamics – name: National Cancer Center Hospital East |
| DOI | 10.1248/yakushi.129.749 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EndPage | 757 |
| ExternalDocumentID | cs7yakug_2009_012906_013_0749_0757648084 |
| GroupedDBID | .55 123 29R 2WC 53G ADBBV AFFNX ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH KQ8 LPU MOJWN OVT P2P RJT RNS RZJ X7J X7M XSB |
| ID | FETCH-LOGICAL-j345t-ddcf3ebc7a36124d1e6053ec6777847884fb3cbf2419deff6f5b637bdd6b795c3 |
| ISSN | 0031-6903 |
| IngestDate | Thu Jul 10 16:12:08 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j345t-ddcf3ebc7a36124d1e6053ec6777847884fb3cbf2419deff6f5b637bdd6b795c3 |
| PageCount | 9 |
| ParticipantIDs | medicalonline_journals_cs7yakug_2009_012906_013_0749_0757648084 |
| PublicationCentury | 2000 |
| PublicationDate | 2009-06-01 |
| PublicationDateYYYYMMDD | 2009-06-01 |
| PublicationDate_xml | – month: 06 year: 2009 text: 2009-06-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationTitle | YAKUGAKU ZASSHI (Journal of the Pharmaceutical Society of Japan) |
| PublicationYear | 2009 |
| Publisher | Pharmaceutical Society of Japan |
| Publisher_xml | – name: Pharmaceutical Society of Japan |
| SSID | ssib002222518 ssib002223935 ssib000959844 ssib002822080 ssib003105265 ssib023161479 ssj0023355 ssib000576198 ssib002499502 ssib003105266 ssib000937675 ssib000972830 ssib001536036 ssib002222551 ssib058494605 ssib058494604 |
| Score | 1.9446788 |
| Snippet | This study was aimed to perform clinical trial simulations to evaluate the dose reduction strategy of docetaxel for Japanese patients with liver dysfunction,... |
| SourceID | medicalonline |
| SourceType | Publisher |
| StartPage | 749 |
| Title | Clinical Trial Simulations for Dosage Optimization of Docetaxel in Patients with Liver Dysfunction, Based on a Log-binominal Regression for Febrile Neutropenia |
| URI | http://mol.medicalonline.jp/en/journal/download?GoodsID=cs7yakug/2009/012906/013&name=0749-0757e |
| Volume | 129 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry issn: 0031-6903 databaseCode: HH5 dateStart: 18810101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: http://abc-chemistry.org/ omitProxy: true ssIdentifier: ssj0023355 providerName: ABC ChemistRy – providerCode: PRVBFR databaseName: Free Medical Journals issn: 0031-6903 databaseCode: DIK dateStart: 19470101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: http://www.freemedicaljournals.com omitProxy: true ssIdentifier: ssj0023355 providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals issn: 0031-6903 databaseCode: GX1 dateStart: 0 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php omitProxy: true ssIdentifier: ssj0023355 providerName: Geneva Foundation for Medical Education and Research |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9NAFB6FcgEhxCp2zQH14rgkGdtjn5DVUJKGNBVJROklmvHSuCixVNsS6Z_hb3LkPS_xuEWiwCFOxvEmz3zvfW_mLYS8BTPWBi3t6RJ0j26YgukiYFxH9iCY37VCH4OTx0fWYG4cnpgnrdZPxWspS-Wed_nbuJJ_6VXYB_2KUbJ_0bPbi8IO-A39C1voYdjeqI_3q7DGWV57Yxqtssq1Db0H-zF6jWkTkAqrMtwSuSHolSAV3wPMtoEp-qM6yO0Temlo_U2C6i53-8iXJBJgpei1jAV-0ZSOi0pgn4Ozwou2cFY8APMaZAzIzSzFKf51JFTq-9UdzT_CRzt1p9PBEKmtwoaR_x4vG_PrlUMp_HsIKn2tTFqMxGW2jC5ibXLqfnG3mmWAMXuxzLTx8MgdD2W136sPSONkGWlTdzYRjQkPp3bMyofoH55FFfasq4PxzxrCvnzU6Jro5kXq1JIF8CJt9jUF0zMwaGIjvmXwtNB09rbnNbJ2ewnHg86wzKezyGf7LPhiC6Bs0IbLW4bdsY1b5HYP9BEWHekPRwqRxuklhSg7V7LuOKZjq3ULHI6Z3BQizKwOUxPhgdxWWEjeVtaDkSU6KnEGQ9jsNNbbex1F0oNR0KirULS39wOjAWhfvf4LLNcxlCxAZbvOismYWdQaKbusTMIFb_vdlXd9l9xbFUuYRSoZhQ3OHpD75cClboHJh6R1Lh6R3XLQbNp0Voc1Jm26S4_rDPGbx-RHBVyaA5cqwKWAJFoAl6rApXFIt8Cl0ZpWwKUIXJoDlyrAbdMcthTOFLQBW1rDNr9ZCVuqwPYJmR98mO0P9LJSin7ODDPVfd8LWSA9LhhYLIbfDeDlssCzOAdRzG3bCCXzZAh03fGDMLRCU1qMS9-3JHdMjz0lO-t4HTwjlHX8Xg9Gk8-FbQSW6YQe95jsdi1hBkAGnpP3jfe_KOVhsrjpkH_x31d4Se7UguEV2UkvsuA12AapfJPD6Behc_xQ |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Trial+Simulations+for+Dosage+Optimization+of+Docetaxel+in+Patients+with+Liver+Dysfunction%2C+Based+on+a+Log-binominal+Regression+for+Febrile+Neutropenia&rft.jtitle=YAKUGAKU+ZASSHI+%28Journal+of+the+Pharmaceutical+Society+of+Japan%29&rft.au=Kazuhiro+OZAWAa&rft.au=Hironobu+MINAMIb&rft.au=c&rft.au=Hitoshi+SATOa&rft.date=2009-06-01&rft.pub=Pharmaceutical+Society+of+Japan&rft.issn=0031-6903&rft.volume=129&rft.issue=6&rft.spage=749&rft.epage=757&rft_id=info:doi/10.1248%2Fyakushi.129.749&rft.externalDocID=cs7yakug_2009_012906_013_0749_0757648084 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6903&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6903&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6903&client=summon |